Press Releases

BASKING RIDGE, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J.

BASKING RIDGE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J.

Significant clinical progress achieved in studies evaluating LSTA1 including first patients treated in BOLSTER (3 solid tumor basket trial) and continued rapid enrollment in ASCEND Orphan drug designations granted for LSTA1 in malignant glioma (U.S.) and pancreatic cancer (EU) Company to host

BASKING RIDGE, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the

Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standard-of-care versus standard-of-care alone in subjects with advanced solid tumors including cholangiocarcinoma, head and neck squamous cell carcinoma, and esophageal squamous cell

BASKING RIDGE, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that

BASKING RIDGE, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J.

Gregory Berkin, Chief Information Officer of Lisata, to participate in keynote discussion on CISO leadership and managing the risks of artificial intelligence BASKING RIDGE, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a

David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, joins an esteemed KOL panel to discuss solid tumor treatments, hosted by WBB Securities. Click here for Register

Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standards of care versus standards of care alone in subjects with advanced solid tumors including cholangiocarcinoma, head and neck squamous cell carcinoma, or esophageal squamous cell